常见化疗药物对免疫酶促反应的干扰效应

摘要
图/表
参考文献(0)
相关文章 (1)

全文: PDF (1554 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的: 探讨常见化疗药物对标记酶免疫分析技术的影响。方法: 将干扰药物烷化剂（环磷酰胺），抗代谢药（阿糖胞苷、氟尿嘧啶、吉西他滨、地西他滨），抗肿瘤抗生素（依托泊苷），抗肿瘤植物成分药（长春新碱、紫杉醇、多西他赛），其他抗肿瘤药（顺铂、奥沙利铂、卡铂、奈达铂、伊立替康），抗肿瘤靶向药（硼替佐米、郝赛汀、培美曲塞二钠）分别加入辣根过氧化物酶（HRP）+ 四甲基联苯胺（TMB）反应体系中，用酶标仪测光密度值；同时加入碱性磷酸酶（ALP）+ 3-(2′-螺旋金刚烷)-4-甲氧基-4-(3″-磷酰氧基)苯-1,2-二氧杂环丁烷（AMPPD）反应体系中，用化学发光仪测相对发光强度值。结果：在HRP酶标反应体系中，与对照组相比，吉西他滨、硼替佐米、多西他赛、紫杉醇、氟尿嘧啶、依托泊苷均显示了不同程度的负向干扰（P<0.05或P<0.01），其中，吉西他滨、多西他赛、紫杉醇、氟尿嘧啶、依托泊苷的干扰效应均呈剂量依赖性。在ALP酶标反应体系中，与对照组相比，硼替佐米、多西他赛、紫杉醇、依托泊苷、伊立替康、地西他滨、培美曲塞二钠均显示了不同程度的负向干扰（P<0.05或P<0.01），其中，多西他赛、紫杉醇、伊立替康、地西他滨、培美曲塞二钠的干扰效应均呈剂量依赖性。在两种酶反应体系中，多西他赛和紫杉醇在人体血样药物峰浓度时对HRP和ALP酶活性仍具有明显抑制作用。结论：多西他赛、紫杉醇两种化疗药物对HRP和ALP免疫酶促反应体系存在明显干扰作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张助
	毛朝明
	蒋茜
	丁超
	刘佳梦
	康萍

关键词 ：化疗药物, 酶促反应, 标记免疫分析

Abstract：Objective: To explore the interfering effects of common chemotherapy drugs on enzymelabeled immunoassay. Methods: Interfering drug alkylating agents (cyclophosphamide), antimetabolites (cytarabine, fluorouracil, gemcitabine, decitabine), antitumor antibiotics (etoposide), antitumor plant component drugs (vincristine, paclitaxel and docetaxel), other antitumor drugs (cisplatin, oxaliplatin, carboplatin, nedaplatin and irinotecan) and antitumor targeted drugs (bortezomib, hoxetine, pemetrexed disodium) were added into the horseradish peroxidase (HRP)+tetramethylbenzidine (TMB) reaction systems to measure the optical density value with a microplate reader; and the alkaline phosphatase (ALP)+3-(2′-Spiraladamantane)4methoxy4(3″phosphoryloxy) benzene-1,2-dioxetane (AMPPD) reaction system to measure the relative luminous intensity with a chemiluminescence instrument. Results: Compared with the control group, in the HRP enzyme-labeled reaction system, all of gemcitabine, bortezomib, docetaxel, paclitaxel, fluorouracil and etoposide produced different degrees of negative interference (P<0.05 or P<0.01). Among them, the interference effects of gemcitabine, docetaxel, paclitaxel, fluorouracil and etoposide were all dose-dependent. In the ALP enzyme-labeled reaction system, compared with the control group, all of bortezomib, docetaxel, paclitaxel, etoposide, irinotecan, decitabine and pemetrexed disodium produced different degrees of negative interference (P<0.05 or P<0.01). Among them, the interference effects of docetaxel, paclitaxel, irinotecan, decitabine, and pemetrexed disodium were all dosedependent. In the two enzyme reaction systems, docetaxel and paclitaxel still had interference effects at the peak concentration of human blood. Conclusion: Docetaxel and paclitaxel had obvious interference effects on HRP and ALP-labeled immune reaction system.

收稿日期: 2020-05-28

基金资助:国家自然科学基金资助项目（81370889，81900562）；镇江市社会发展项目（SH2019047）

通讯作者: 毛朝明（通讯作者），主任技师，副教授，博士生导师，E-mail: jq1001@ujs.edu.cn

作者简介: 张助（1991—），男，硕士研究生

引用本文:

张助，毛朝明，蒋茜，丁超，刘佳梦，康萍. 常见化疗药物对免疫酶促反应的干扰效应[J]. 江苏大学学报:医学版, 2021, 31(01): 64-68. ZHANG Zhu， MAO Chaoming, JIANG Qian， DING Chao， LIU Jiameng， KANG Ping.

Interfering effects of common chemotherapeutic drugs on immunoenzymatic reaction system

. Journal of Jiangsu University(Medicine Edition), 2021, 31(01): 64-68.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2021/V31/I01/64

［1］Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing risk\[J\]. Ann Clin Biochem, 2011, 48(5): 418-432.

［2］Kailajarvi M, Takala T, Gronroos P, et al. Reminders of drug effects on laboratory test results\[J\]. Clin Chem, 2000, 46(9): 1395-1400.

［3］Owen LJ, Monaghan PJ, Armstrong A, et al. Oestradiol measurement during fulvestrant treatment for breast cancer\[J\]. Br J Cancer, 2019, 120(4): 404-406.

［4］Paragliola RM, Corsello A, Papi G, et al. Immunoassay interference on thyroid function tests during treatment with Nivolumab\[J\]. Thyroid, 2020, 30(7): 1091-1094.

［5］汪晨，吴洁，宗晨，等. 化学发光免疫分析方法与应用进展\[J\]. 分析化学， 2012, 1(40): 3-10.

［6］Marks V. Falsepositive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries\[J\]. Clin Chem, 2002, 48(11): 2008-2016.

［7］Sher PP. Drug interferences with clinical laboratory tests\[J\]. Drugs, 1982, 24(1): 24-63.

［8］侯立安，国秀芝，邱玲，等. 羟苯磺酸钙对酶法游离脂肪酸检测的负干扰\[J\]. 检验医学, 2016, 31(11): 936-940.

［9］Ismail AA. Identifying and reducing potentially wrong immunoassay results even when plausible and “notunreasonable”\[J\]. Adv Clin Chem, 2014, 66(3): 241-294.

［10］Vogeser M, Seger C. Irregular analytical errors in diagnostic testinga novel concept\[J\]. Clin Chem Lab Med, 2018, 56(3): 386-396.

［11］Clerico A, Belloni L, Carrozza C, et al. A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods\[J\]. Clin Chem Lab Med, 2018, 56(3): 397-402.

［12］Joerger M. Metabolism of the taxanes including nabpaclitaxel\[J\]. Expert Opin Drug Metab Toxicol, 2015, 11(5): 691-702.